Health Care & Life Sciences » Pharmaceuticals | Corline Biomedical AB

Corline Biomedical AB

Corline Biomedical AB
Stock Exchange First North Sweden
EPS
SEK0.45
Market Cap
SEK378.6 M
Shares Outstanding
15.77 M
Public Float
-

Profile

Address
Lefflersgatan 5
Uppsala UP 754 50
Sweden
Employees -
Website http://www.corline.se
Updated 09/14/2018
Corline Biomedical AB engages in the research, development, and commercialization of heparin based solutions. Its products intend to improve kidney transplantation, cell therapies, and applications. It operates under the following trademarks: CHC, Renaparin, Cytoparin, and CHS.

Financials

View All
Created with Highcharts 5.0.14Corline Biomedical ABNet Income. Fiscal year is January-December. All values SEK Thousands.2 4872 4872 5122 5125 8455 8455 2485 2487 8107 8102013201420152016201702k4k6k8k10k
Created with Highcharts 5.0.14Corline Biomedical ABSales/Revenue. Fiscal year is January-December. All values SEK Thousands.1 7871 7871 6831 6831 0371 037947947638638201320142015201620170500100015002000

Henrik Krook
Non-Executive Director
Lars Fredrik Sunnanväder
Non-Executive Director